Phase I Study of Nimotuzumab in Solid Tumours
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Received Date ICMJE | August 25, 2006 | ||||||||
Last Updated Date | February 27, 2007 | ||||||||
Start Date ICMJE | June 2005 | ||||||||
Primary Completion Date | |||||||||
Current Primary Outcome Measures ICMJE | |||||||||
Original Primary Outcome Measures ICMJE | |||||||||
Change History | Complete list of historical versions of study NCT00369252 on ClinicalTrials.gov Archive Site | ||||||||
Current Secondary Outcome Measures ICMJE | |||||||||
Original Secondary Outcome Measures ICMJE | |||||||||
Current Other Outcome Measures ICMJE | |||||||||
Original Other Outcome Measures ICMJE | |||||||||
Descriptive Information | |||||||||
Brief Title ICMJE | Phase I Study of Nimotuzumab in Solid Tumours | ||||||||
Official Title ICMJE | A Phase I Study of TheraCIM-hR3 (YMB1000) in Patients With Solid Tumours | ||||||||
Brief Summary | This is a phase I trial of nimotuzumab that will be conducted in patients with advanced incurable solid tumors. This is a dose-seeking study to determine the maximum tolerated and recommended phase II doses of nimotuzumab that can be safely given to patients with advanced and/or metastatic solid tumors. |
||||||||
Detailed Description | This is an open-label, dose-escalating, phase I trial of nimotuzumab in patients with advanced incurable solid tumors. The objective of this study is to determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of nimotuzumab that can be given in a weekly schedule in patients with advanced and/or metastatic solid tumor cancer. This study will also examine the safety, pharmacodynamics and preliminary efficacy of nimotuzumab in this patient population. |
||||||||
Study Type ICMJE | Interventional | ||||||||
Study Phase | Phase 1 | ||||||||
Study Design ICMJE | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
||||||||
Condition ICMJE | Advanced and/or Metastatic Solid Tumours | ||||||||
Intervention ICMJE | Drug: Nimotuzumab (TheraCIM h-R3) | ||||||||
Study Arm (s) | |||||||||
Publications * | |||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status ICMJE | Completed | ||||||||
Enrollment ICMJE | 18 | ||||||||
Completion Date | |||||||||
Primary Completion Date | |||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||
Gender | Both | ||||||||
Ages | 18 Years and older | ||||||||
Accepts Healthy Volunteers | No | ||||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||||
Location Countries ICMJE | Canada | ||||||||
Administrative Information | |||||||||
NCT Number ICMJE | NCT00369252 | ||||||||
Other Study ID Numbers ICMJE | YMB1000-007 | ||||||||
Has Data Monitoring Committee | |||||||||
Responsible Party | |||||||||
Study Sponsor ICMJE | YM BioSciences | ||||||||
Collaborators ICMJE | CIMYM BioSciences | ||||||||
Investigators ICMJE |
|
||||||||
Information Provided By | YM BioSciences | ||||||||
Verification Date | February 2007 | ||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |